









Markets
/
Stocks
/
nasdaq-ltrn
/

Lantern Pharma Inc

LTRN

4.030USD

-0.040-0.98%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

43.46MMarket Cap

LossP/E TTM



Lantern Pharma Inc

4.030

-0.040-0.98%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

252 / 506

Overall Ranking

411 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

20.000

Target Price

+391.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.73.

Overvalued

The company’s latest PE is -2.26, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.78M shares, decreasing 13.49% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 363.72K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.28, which is -0.12% below the recent high of -2.28 and -58.30% above the recent low of -3.61.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 252/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Lantern Pharma Inc is 20.00, with a high of 25.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

20.000

Target Price

+391.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Lantern Pharma Inc

LTRN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.96, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 4.60 and the support level at 3.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.96

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Sell

RSI(14)

47.255

Neutral

STOCH(KDJ)(9,3,3)

43.105

Buy

ATR(14)

0.316

Low Volatility

CCI(14)

-19.994

Neutral

Williams %R

58.947

Sell

TRIX(12,20)

-0.474

Sell

StochRSI(14)

87.246

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.984

Buy

MA10

3.975

Buy

MA20

4.112

Sell

MA50

4.269

Sell

MA100

3.834

Buy

MA200

3.838

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 35.06%, representing a quarter-over-quarter decrease of 6.50%. The largest institutional shareholder is The Vanguard, holding a total of 363.72K shares, representing 3.37% of shares outstanding, with 0.13% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bios Equity Partners, LP.

1.08M

-12.79%

Biological Mimetics, Inc

844.13K

-7.66%

Prophase Labs Inc

631.20K

The Vanguard Group, Inc.

Star Investors

363.72K

CM Management, LLC

200.00K

Geode Capital Management, L.L.C.

90.50K

+4.06%

Renaissance Technologies LLC

Star Investors

88.80K

+1.72%

GWM Advisors LLC

59.92K

-12.34%

Voss Capital LLC

50.00K

Keyser (Donald Jeffrey PH.D)

45.76K

+9.14%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.23, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.